

# REVIEWS

1. Schmidt, D. & Sillanpää, M. Evidence-based review on the natural history of the epilepsies. *Curr. Opin. Neurol.* **25**, 159–163 (2012).
2. Berg, A. T. *et al.* Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009. *Epilepsia* **51**, 676–685 (2010).
3. Tellez-Zenteno, J. F., Patten, S. B., Jette, N., Williams, J. & Wiebe, S. Psychiatric comorbidity in epilepsy: a population-based analysis. *Epilepsia* **48**, 2336–2344 (2007).
4. Löscher, W. & Schmidt, D. Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma. *Epilepsia* **52**, 657–678 (2011).  
**This is the first review to show that modern AEDs fail to address important unmet treatment needs of patients with epilepsy.**
5. Sillanpää, M. & Schmidt, D. Natural history of treated childhood-onset epilepsies: prospective, long-term population-based study. *Brain* **129**, 617–624 (2006).  
**The study identified four clinically important seizure outcome patterns of new-onset epilepsy and the factors that allow their early prediction.**
6. Brodie, M. J., Barry, S. J., Bamagous, G. A., Norrie, J. D. & Kwan, P. Patterns of treatment response in newly diagnosed epilepsy. *Neurology* **78**, 1548–1554 (2012).
7. Temkin, N. R. Preventing and treating posttraumatic seizures: the human experience. *Epilepsia* **50** (Suppl. 2), 10–13 (2009).
8. Schmidt, D. Is antiepileptogenesis a realistic goal in clinical trials? Concerns and new horizons. *Epilept. Disord.* **14**, 105–113 (2012).
9. Blumenfeld, H. *et al.* Early treatment suppresses the development of spike-wave epilepsy in a rat model. *Epilepsia* **49**, 400–409 (2008).  
**This is the first study to show the anti-epileptogenic activity of an AED in a genetic model of epilepsy.**
10. Russo, E. *et al.* Comparison of the antiepileptogenic effects of an early long-term treatment with ethosuximide or levetiracetam in a genetic animal model of absence epilepsy. *Epilepsia* **51**, 1560–1569 (2010).
11. Marson, A. G. *et al.* The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. *Lancet* **369**, 1000–1015 (2007).
12. Marson, A. G. *et al.* The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. *Lancet* **369**, 1016–1026 (2007).
13. Trinka, E. *et al.* KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy. *J. Neurol. Neurosurg. Psychiatry* **84**, 1138–1147 (2013).
14. Brodie, M. J. *et al.* Enzyme induction with antiepileptic drugs: cause for concern? *Epilepsia* **54**, 11–27 (2013).
15. Beyenburg, S., Stavem, K. & Schmidt, D. Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: systematic review and meta-analysis. *Epilepsia* **51**, 7–26 (2010).
16. White, H. S., Smith-Yockman, M., Srivastava, A. & Wilcox, K. S. in *Models of seizures & epilepsy* (eds Pitkänen, A., Schwartzkroin, P. A. & Moshé, S. L.) 539–549 (Elsevier, 2006).
17. Bialer, M. & White, H. S. Key factors in the discovery and development of new antiepileptic drugs. *Nature Rev. Drug Discov.* **9**, 68–82 (2010).
18. Perucca, E., French, J. & Bialer, M. Development of new antiepileptic drugs: challenges, incentives, and recent advances. *Lancet Neurol.* **6**, 793–804 (2007).
19. Putnam, T. J. & Merritt, H. H. Experimental determination of the anticonvulsant properties of some phenyl derivatives. *Science* **85**, 525–526 (1937).
20. Toman, J. E. P., Swinyard, E. A. & Goodman, L. S. Properties of maximal seizures and their alteration by anticonvulsant drugs and other agents. *J. Neurophysiol.* **9**, 231–239 (1946).
21. Löscher, W. Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs. *Seizure* **20**, 359–368 (2011).
22. Everett, G. M. & Richards, R. K. Comparative anticonvulsant action of 3,5,5-trimethylxazolindione-2,4-dione (Tridione), dilantin and phenobarbital. *J. Pharmacol. Exp. Ther.* **81**, 402–407 (1944).
23. Swinyard, E. A. Laboratory assay of clinically effective antiepileptic drugs. *J. Am. Pharm. Assoc.* **38**, 201–204 (1949).
24. Swinyard, E. A., Brown, W. C. & Goodman, L. S. Comparative assay of antiepileptic drugs in mice and rats. *J. Pharmacol. Exp. Ther.* **106**, 319–330 (1952).
25. Barton, M. E., Klein, B. D., Wolf, H. H. & White, H. S. Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. *Epilepsy Res.* **47**, 217–228 (2001).
26. Cossart, R., Bernard, C. & Ben-Ari, Y. Multiple facets of GABAergic neurons and synapses: multiple facets of GABA signalling in epilepsies. *Trends Neurosci.* **28**, 108–115 (2005).
27. Perucca, E. What clinical trial designs have been used to test antiepileptic drugs and do we need to change them? *Epilept. Disord.* **14**, 124–131 (2012).
28. Friedman, D. & French, J. A. Clinical trials for therapeutic assessment of antiepileptic drugs in the 21st century: obstacles and solutions. *Lancet Neurol.* **11**, 827–834 (2012).
29. Krall, R. L., Penry, J. K., Kupferberg, H. J. & Swinyard, E. A. Antiepileptic drug development: I. History and a program for progress. *Epilepsia* **19**, 393–408 (1978).
30. Krall, R. L., Penry, J. K., White, B. G., Kupferberg, H. J. & Swinyard, E. A. Antiepileptic drug development: II. Anticonvulsant drug screening. *Epilepsia* **19**, 409–428 (1978).
31. Klitgaard, H. & Verdrup, P. Levetiracetam — the first SV2A ligand for the treatment of epilepsy. *Expert Opin. Drug Discov.* **2**, 1537–1545 (2008).
32. Srivastava, A. K. & White, H. S. Carbamazepine, but not valproate, displays pharmacoresistance in lamotrigine-resistant amygdala kindled rats. *Epilepsy Res.* **104**, 26–34 (2012).
33. Mattson, R. H., Cramer, J. A. & Collins, J. F. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. *N. Engl. J. Med.* **327**, 765–771 (1992).
34. Privitera, M. D. *et al.* Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. *Acta Neurol. Scand.* **107**, 165–175 (2003).
35. Semah, F. *et al.* Is the underlying cause of epilepsy a major prognostic factor for recurrence? *Neurology* **51**, 1256–1262 (1998).
36. Wheless, J. W., Clarke, D. F., Arzimanoglou, A. & Carpenter, D. Treatment of pediatric epilepsy: European expert opinion, 2007. *Epilept. Disord.* **9**, 353–412 (2007).
37. Halford, J. J. *et al.* A randomized, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of adjunctive carisbamate treatment in patients with partial-onset seizures. *Epilepsia* **52**, 816–825 (2011).
38. Baulac, M., Leon, T., O'Brien, T. J., Whalen, E. & Barrett, J. A comparison of pregabalin, lamotrigine, and placebo as adjunctive therapy in patients with refractory partial-onset seizures. *Epilepsy Res.* **91**, 10–19 (2010).
39. Ryvlin, P., Cucherat, M. & Rheims, S. Risk of sudden unexpected death in epilepsy in patients given adjunctive antiepileptic treatment for refractory seizures: a meta-analysis of placebo-controlled randomised trials. *Lancet Neurol.* **10**, 961–968 (2011).
40. Schmidt, D., Beyenburg, S., D'Souza, J. & Stavem, K. Clinical features associated with placebo response in refractory focal epilepsy. *Epilepsy Behav.* **27**, 393–398 (2013).
41. Enck, P., Bingel, U., Schedlowski, M. & Rief, W. The placebo response in medicine: minimize, maximize or personalize? *Nature Rev. Drug Discov.* **12**, 191–204 (2013).
42. Sillanpää, M. & Schmidt, D. Early seizure frequency and aetiology predict long-term medical outcome in childhood-onset epilepsy. *Brain* **132**, 989–998 (2009).
43. Schiller, Y. & Najjar, Y. Quantifying the response to antiepileptic drugs: effect of past treatment history. *Neurology* **70**, 54–65 (2008).
44. Go, C. Y. *et al.* Evidence-based guideline update: medical treatment of infantile spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. *Neurology* **78**, 1974–1980 (2012).
45. Plosker, G. L. Stiripentol: in severe myoclonic epilepsy of infancy (dravet syndrome). *CNS Drugs* **26**, 993–1001 (2012).
46. Glauser, T. *et al.* Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. *Epilepsia* **54**, 551–563 (2013).
47. Löscher, W. & Brandt, C. Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research. *Pharmacol. Rev.* **62**, 668–700 (2010).
48. Pitkänen, A. & Lukasiuk, K. Mechanisms of epileptogenesis and potential treatment targets. *Lancet Neurol.* **10**, 173–186 (2011).
49. Eastman, C. L. *et al.* Antiepileptic and antiepileptogenic performance of carisbamate after head injury in the rat: blind and randomized studies. *J. Pharmacol. Exp. Ther.* **336**, 779–790 (2011).
50. Russo, E. *et al.* mTOR inhibition modulates epileptogenesis, seizures and depressive behavior in a genetic rat model of absence epilepsy. *Neuropharmacology* **69**, 25–36 (2013).
51. Sloviter, R. S. & Bumanglag, A. V. Defining “epileptogenesis” and identifying “antiepileptogenic targets” in animal models of acquired temporal lobe epilepsy is not as simple as it might seem. *Neuropharmacology* **69**, 3–15 (2012).
52. Rogawski, M. A. & Löscher, W. The neurobiology of antiepileptic drugs. *Nature Rev. Neurosci.* **5**, 553–564 (2004).
53. Löscher, W. & Schmidt, D. Epilepsy: perampanel — new promise for refractory epilepsy? *Nature Rev. Neurol.* **8**, 661–662 (2012).
54. Brodie, M. J. *et al.* Antiepileptic drug therapy: does mechanism of action matter? *Epilepsy Behav.* **21**, 490 (2011).
55. Perucca, E. The pharmacology of new antiepileptic drugs: does a novel mechanism of action really matter? *CNS Drugs* **25**, 907–912 (2011).
56. Schmidt, D. Antiepileptic drug discovery: does mechanism of action matter? *Epilepsy Behav.* **21**, 342–343 (2011).
57. Loeb, J. A. Identifying targets for preventing epilepsy using systems biology. *Neurosci. Lett.* **497**, 205–212 (2011).
58. Inoki, K., Corradetti, M. N. & Guan, K. L. Dysregulation of the TSC–mTOR pathway in human disease. *Nature Genet.* **37**, 19–24 (2005).  
**This study describes the emerging evidence for a functional relationship between the mTOR signalling pathway and several genetic diseases.**
59. Vezzani, A. Before epilepsy unfolds: finding the epileptogenesis switch. *Nature Med.* **18**, 1626–1627 (2012).
60. Rytter, R. C. & Wong, M. Mammalian target of rapamycin (mTOR) inhibition: potential for antiseizure, antiepileptogenic, and epileptostatic therapy. *Curr. Neurol. Neurosci. Rep.* **12**, 410–418 (2012).
61. Zeng, L. H., Xu, L., Guttmann, D. H. & Wong, M. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. *Ann. Neurol.* **63**, 444–453 (2008).  
**This study describes the anti-epileptogenic or disease-modifying activity of the mTOR inhibitor rapamycin in a model of tuberous sclerosis, which stimulated clinical trials with this drug.**
62. Cohen, I., Navarro, V., Clemenceau, S., Baulac, M. & Miles, R. On the origin of interictal activity in human temporal lobe epilepsy *in vitro*. *Science* **298**, 1418–1421 (2002).  
**This important study identifies a subpopulation of excitatory pyramidal neurons displaying depolarizing GABA responses in the subicular zone of the hippocampus as the likely pacemaker neurons that initiate epileptic discharges.**
63. Löscher, W., Puskarjov, M. & Kaila, K. Cation-chloride cotransporters NKCC1 and KCC2 as potential targets for novel antiepileptic and antiepileptogenic treatments. *Neuropharmacology* **69**, 62–74 (2013).
64. Dzhalil, V. I. *et al.* NKCC1 transporter facilitates seizures in the developing brain. *Nature Med.* **11**, 1205–1213 (2005).  
**This paper provides experimental evidence that the NKCC1 inhibitor bumetanide could be useful in the treatment of neonatal seizures.**

65. Koyama, R. *et al.* GABAergic excitation after febrile seizures induces ectopic granule cells and adult epilepsy. *Nature Med.* **18**, 1271–1278 (2012). **This paper provides the first experimental evidence that bumetanide exerts an anti-epileptogenic effect: that is, it prevents the development of epilepsy after complex febrile seizures.**
66. Brandt, C., Nozadz, M., Heuchert, N., Rattka, M. & Löscher, W. Disease-modifying effects of phenobarbital and the NKCC1 inhibitor bumetanide in the pilocarpine model of temporal lobe epilepsy. *J. Neurosci.* **30**, 8602–8612 (2010).
67. Eftekhari, S. *et al.* Bumetanide reduces seizure frequency in patients with temporal lobe epilepsy. *Epilepsia* **54**, e9–e12 (2012).
68. Vezzani, A., Balosso, S. & Ravizza, T. The role of cytokines in the pathophysiology of epilepsy. *Brain Behav. Immun.* **22**, 797–803 (2008).
69. Vezzani, A., French, J., Bartfai, T. & Baram, T. Z. The role of inflammation in epilepsy. *Nature Rev. Neurol.* **7**, 31–40 (2011).
70. Vezzani, A., Friedman, A. & Dingledine, R. J. The role of inflammation in epileptogenesis. *Neuropharmacology* **69**, 16–24 (2013).
71. Vezzani, A. & Baram, T. Z. New roles for interleukin-1 beta in the mechanisms of epilepsy. *Epilepsy Curr.* **7**, 45–50 (2007).
72. Rasmussen, T., Olszewski, J. & Lloyd-Smith, D. Focal seizures due to chronic localized encephalitis. *Neurology* **8**, 435–445 (1958).
73. Vezzani, A., Maroso, M., Balosso, S., Sanchez, M. A. & Bartfai, T. IL-1 receptor/Toll-like receptor signaling in infection, inflammation, stress and neurodegeneration couples hyperexcitability and seizures. *Brain Behav. Immun.* **25**, 1281–1289 (2011).
74. Maroso, M. *et al.* Interleukin-1 beta biosynthesis inhibition reduces acute seizures and drug resistant chronic epileptic activity in mice. *Neurotherapeutics* **8**, 304–315 (2011).
75. Bialer, M. *et al.* Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI). *Epilepsy Res.* **103**, 2–30 (2013).
76. Vezzani, A. *et al.* Powerful anticonvulsant action of IL-1 receptor antagonist on intracerebral injection and astrocytic overexpression in mice. *Proc. Natl Acad. Sci. USA* **97**, 11534–11539 (2000).
77. Vezzani, A. *et al.* Functional role of inflammatory cytokines and anti-inflammatory molecules in seizures and epileptogenesis. *Epilepsia* **43** (Suppl. 5), 30–35 (2002).
78. Librizzi, L., Noe, F., Vezzani, A., De Curtis, M. & Ravizza, T. Seizure-induced brain-borne inflammation sustains seizure recurrence and blood–brain barrier damage. *Ann. Neurol.* **72**, 82–90 (2012). **This paper describes how the human recombinant IL-1 $\beta$ R antagonist anakinra terminates seizures, prevents their recurrence and resolves seizure-associated BBB breakdown in an animal model, supporting the use of specific anti-inflammatory drugs for the treatment of refractory seizures.**
79. Maroso, M. *et al.* Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. *Nature Med.* **16**, 413–419 (2010). **This study indicates that TLR4 and high-mobility group box protein 1 contribute to the generation and perpetuation of epileptic activity and might form novel targets for the treatment of pharmacoresistant seizures.**
80. Fabene, P. F. *et al.* A role for leukocyte–endothelial adhesion mechanisms in epilepsy. *Nature Med.* **14**, 1377–1383 (2008). **This paper proposes a novel target (factors involved in leukocyte–endothelial interactions, such as VLA4) for the prevention and treatment of epilepsy; VLA4 is successfully being targeted in the treatment of multiple sclerosis.**
81. Fabene, P. F., Laudanna, C. & Constantin, G. Leukocyte trafficking mechanisms in epilepsy. *Mol. Immunol.* **55**, 100–104 (2013).
82. Sotgiu, S., Murrighill, M. R. & Constantin, G. Treatment of refractory epilepsy with natalizumab in a patient with multiple sclerosis. Case report. *BMC Neurol.* **10**, 84 (2010).
83. Friedman, A., Kaufer, D. & Heinemann, U. Blood–brain barrier breakdown-inducing astrocytic transformation: novel targets for the prevention of epilepsy. *Epilepsy Res.* **85**, 142–149 (2009).
84. Shlosberg, D., Benfla, M., Kaufer, D. & Friedman, A. Blood–brain barrier breakdown as a therapeutic target in traumatic brain injury. *Nature Rev. Neurol.* **6**, 393–403 (2010).
85. Heinemann, U., Kaufer, D. & Friedman, A. Blood–brain barrier dysfunction, TGF $\beta$  signaling, and astrocyte dysfunction in epilepsy. *Glia* **60**, 1251–1257 (2012).
86. Frigerio, F. *et al.* Long-lasting pro-ictogenic effects induced *in vivo* by rat brain exposure to serum albumin in the absence of concomitant pathology. *Epilepsia* **53**, 1887–1897 (2012).
87. Cacheaux, L. P. *et al.* Transcriptome profiling reveals TGF- $\beta$  signaling involvement in epileptogenesis. *J. Neurosci.* **29**, 8927–8935 (2009). **This paper identifies the TGF $\beta$  pathway as a novel putative epileptogenic signalling cascade and a therapeutic target for the prevention of injury-induced epilepsy.**
88. Kobow, K. *et al.* Finding a better drug for epilepsy: antiepileptogenesis targets. *Epilepsia* **53**, 1868–1876 (2012).
89. Roopra, A., Dingledine, R. & Hsieh, J. Epigenetics and epilepsy. *Epilepsia* **53** (Suppl. 9), 2–10 (2012).
90. McClelland, S. *et al.* Neuron-restrictive silencer factor-mediated hyperpolarization-activated cyclic nucleotide gated channelopathy in experimental temporal lobe epilepsy. *Ann. Neurol.* **70**, 454–464 (2011).
91. Jimenez-Mateos, E. M. *et al.* Silencing microRNA-134 produces neuroprotective and prolonged seizure-suppressive effects. *Nature Med.* **18**, 1087–1094 (2012). **This paper describes the upregulation of microRNA-134, a brain-specific, activity-regulated microRNA, in epileptic tissue and shows that silencing of microRNA-134 renders mice refractory to seizures and hippocampal injury caused by status epilepticus.**
92. Kobow, K. & Blumcke, I. The emerging role of DNA methylation in epileptogenesis. *Epilepsia* **53** (Suppl. 9), 11–20 (2012).
93. Mazzuferi, M. *et al.* Nrf2 defense pathway: experimental evidence for its protective role in epilepsy. *Ann. Neurol.* <http://dx.doi.org/10.1002/ana.23940> (2013).
94. Winden, K. D. *et al.* A systems level, functional genomics analysis of chronic epilepsy. *PLoS ONE* **6**, e20763 (2011).
95. Kraft, A. D., Lee, J. M., Johnson, D. A., Kan, Y. W. & Johnson, J. A. Neuronal sensitivity to kainic acid is dependent on the Nrf2-mediated actions of the antioxidant response element. *J. Neurochem.* **98**, 1852–1865 (2006).
96. Scannevin, R. H. *et al.* Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. *J. Pharmacol. Exp. Ther.* **341**, 274–284 (2012).
97. Schadt, E. E. *et al.* An integrative genomics approach to infer causal associations between gene expression and disease. *Nature Genet.* **37**, 710–717 (2005).
98. Lukasiuk, K., Dabrowski, M., Adach, A. & Pitkanen, A. Epileptogenesis-related genes revisited. *Prog. Brain Res.* **158**, 223–241 (2006).
99. Bertram, E. H., Zhang, D. X., Mangan, P., Fountain, N. & Rempe, D. Functional anatomy of limbic epilepsy: a proposal for central synchronization of a diffusely hyperexcitable network. *Epilepsy Res.* **32**, 194–205 (1998).
100. Engel, J. *et al.* Connectomics and epilepsy. *Curr. Opin. Neurol.* **26**, 186–194 (2013).
101. Wiebe, S. & Jette, N. Pharmacoresistance and the role of surgery in difficult to treat epilepsy. *Nature Rev. Neurol.* **8**, 669–677 (2012).
102. Hopkins, A. L. Network pharmacology: the next paradigm in drug discovery. *Nature Chem. Biol.* **4**, 682–690 (2008).
103. Ainsworth, C. Networking for new drugs. *Nature Med.* **17**, 1166–1168 (2011).
104. Margineanu, D. G. Systems biology impact on antiepileptic drug discovery. *Epilepsy Res.* **98**, 104–115 (2012).
105. Löscher, W., Rundfeldt, C. & Hönack, D. Low doses of NMDA receptor antagonists synergistically increase the anticonvulsant effect of the AMPA receptor antagonist NBQX in the kindling model of epilepsy. *Eur. J. Neurosci.* **5**, 1545–1550 (1993).
106. Löscher, W. & Ebert, U. Basic mechanisms of seizure propagation: targets for rational drug design and rational polypharmacy. *Epilepsy Res. Suppl.* **11**, 17–44 (1996).
107. Kwon, Y. S. *et al.* Neuroprotective and antiepileptogenic effects of combination of anti-inflammatory drugs in the immature brain. *J. Neuroinflamm.* **10**, 30 (2013).
108. Löscher, W. & Potschka, H. Drug resistance in brain diseases and the role of drug efflux transporters. *Nature Rev. Neurosci.* **6**, 591–602 (2005).
109. Löscher, W. & Langer, O. Imaging of P-glycoprotein function and expression to elucidate mechanisms of pharmacoresistance in epilepsy. *Curr. Top. Med. Chem.* **10**, 1785–1791 (2010).
110. Feldmann, M. & Koeppe, M. P-glycoprotein imaging in temporal lobe epilepsy: *in vivo* PET experiments with the Pgp substrate [ $^{11}$ C]-verapamil. *Epilepsia* **53** (Suppl. 6), 60–63 (2012).
111. Feldmann, M. *et al.* P-glycoprotein expression and function in patients with temporal lobe epilepsy: a case-control study. *Lancet Neurol.* **12**, 777–785 (2013).
112. Autry, A. R., Trevathan, E., Van Naarden, B. K. & Yeargin-Allsopp, M. Increased risk of death among children with Lennox–Gastaut syndrome and infantile spasms. *J. Child Neurol.* **25**, 441–447 (2010).
113. Briggs, D. E., Lee, C. M., Spiegel, K. & French, J. A. Reduction of secondarily generalized tonic-clonic (SGTC) seizures with pregabalin. *Epilepsy Res.* **82**, 86–92 (2008).
114. Schmidt, D. & Löscher, W. Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. *Epilepsia* **46**, 858–877 (2005).
115. Remy, S. & Beck, H. Molecular and cellular mechanisms of pharmacoresistance in epilepsy. *Brain* **129**, 18–35 (2006).
116. Schmidt, D. & Löscher, W. New developments in antiepileptic drug resistance: an integrative view. *Epilepsy Curr.* **9**, 47–52 (2009).
117. Potschka, H. Role of CNS efflux drug transporters in antiepileptic drug delivery: overcoming CNS efflux drug transport. *Adv. Drug Deliv. Rev.* **64**, 943–952 (2012).
118. Brandt, C., Bethmann, K., Gastens, A. M. & Löscher, W. The multidrug transporter hypothesis of drug resistance in epilepsy: proof-of-principle in a rat model of temporal lobe epilepsy. *Neurobiol. Dis.* **24**, 202–211 (2006).
119. Löscher, W., Luna-Tortos, C., Römermann, K. & Fedowitz, M. Do ATP-binding cassette transporters cause pharmacoresistance in epilepsy? Problems and approaches in determining which antiepileptic drugs are affected. *Curr. Pharm. Des.* **17**, 2808–2828 (2011).
120. Zhang, C., Kwan, P., Zuo, Z. & Baum, L. The transport of antiepileptic drugs by P-glycoprotein. *Adv. Drug Deliv. Rev.* **64**, 930–942 (2012).
121. Löscher, W., Klotz, U., Zimprich, F. & Schmidt, D. The clinical impact of pharmacogenetics on the treatment of epilepsy. *Epilepsia* **50**, 1–23 (2009).
122. Kaminski, R. M., Matagne, A., Patsalos, P. N. & Klitgaard, H. Benefit of combination therapy in epilepsy: a review of the preclinical evidence with levetiracetam. *Epilepsia* **50**, 387–397 (2009).
123. Lason, W., Dudra-Jastrzebska, M., Rejdak, K. & Czuczwar, S. J. Basic mechanisms of antiepileptic drugs and their pharmacokinetic/pharmacodynamic interactions: an update. *Pharmacol. Rep.* **63**, 271–292 (2011).
124. Czuczwar, S. J. *et al.* Pharmacodynamic interactions between antiepileptic drugs: preclinical data based on isobolography. *Expert Opin. Drug Metab. Toxicol.* **5**, 131–136 (2009).
125. Brodie, M. J. & Sills, G. J. Combining antiepileptic drugs — rational polytherapy? *Seizure* **20**, 369–375 (2011).
126. Perucca, E. & Meador, K. J. Adverse effects of antiepileptic drugs. *Acta Neurol. Scand. Suppl.* **181**, 30–35 (2005).
127. Schmidt, D. Drug treatment of epilepsy: options and limitations. *Epilepsy Behav.* **15**, 56–65 (2009).
128. Meldrum, B. Do preclinical seizure models preselect certain adverse effects of antiepileptic drugs. *Epilepsy Res.* **50**, 33–40 (2002).
129. Löscher, W. & Hönack, D. Responses to NMDA receptor antagonists altered by epileptogenesis. *Trends Pharmacol. Sci.* **12**, 52 (1991).
130. Löscher, W. & Schmidt, D. Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation? *Epilepsy Res.* **17**, 95–134 (1994).
131. Klitgaard, H., Matagne, A. & Lambert, Y. Use of epileptic animals for adverse effect testing. *Epilepsy Res.* **50**, 55–65 (2002).

# REVIEWS

132. Bowden, C. L. & Singh, V. Lamotrigine (Lamictal IR) for the treatment of bipolar disorder. *Expert Opin. Pharmacother.* **13**, 2565–2571 (2012).
133. Mula, M., Kanner, A. M., Schmitz, B. & Schachter, S. Antiepileptic drugs and suicidality: an expert consensus statement from the Task Force on Therapeutic Strategies of the ILAE Commission on Neuropsychobiology. *Epilepsia* **54**, 199–203 (2013).
134. Rogawski, M. A. & Löscher, W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. *Nature Med.* **10**, 685–692 (2004). **This paper describes a concept for explaining the therapeutic effects of AEDs in neuropathic pain, bipolar disorders, migraine and other non-epileptic diseases.**
135. Bialer, M. *et al.* Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). *Epilepsy Res.* **92**, 89–124 (2010).
136. Kanner, A. M. Can neurobiological pathogenic mechanisms of depression facilitate the development of seizure disorders? *Lancet Neurol.* **11**, 1093–1102 (2012).
137. Rocha, L. *et al.* Dopamine abnormalities in the neocortex of patients with temporal lobe epilepsy. *Neurobiol. Dis.* **45**, 499–507 (2012).
138. Szot, P. Common factors among Alzheimer's disease, Parkinson's disease, and epilepsy: possible role of the noradrenergic nervous system. *Epilepsia* **53** (Suppl. 1), 61–66 (2012).
139. Engel, J. Jr. Biomarkers in epilepsy: introduction. *Biomark. Med.* **5**, 537–544 (2011).
140. Simonato, M. *et al.* Finding a better drug for epilepsy: preclinical screening strategies and experimental trial design. *Epilepsia* **53**, 1860–1867 (2012).
141. Engel, J. Jr., Bragin, A., Staba, R. & Mody, I. High-frequency oscillations: what is normal and what is not? *Epilepsia* **50**, 598–604 (2009).
142. Kobeissy, F. H. *et al.* Leveraging biomarker platforms and systems biology for rehabilitomics and biologics effectiveness research. *PM & R* **3**, S139–S147 (2011).
143. Hampel, H., Lista, S. & Khachaturian, Z. S. Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot. *Alzheimers Dement.* **8**, 312–336 (2012).
144. Kola, I. The state of innovation in drug development. *Clin. Pharmacol. Ther.* **83**, 227–230 (2008). **This paper describes how innovation in drug development necessitates the availability of robust and objective biomarkers for carrying out early proof-of-concept studies.**
145. Munos, B. Lessons from 60 years of pharmaceutical innovation. *Nature Rev. Drug Discov.* **8**, 959–968 (2009).
146. Paul, S. M. *et al.* How to improve R&D productivity: the pharmaceutical industry's grand challenge. *Nature Rev. Drug Discov.* **9**, 203–214 (2010). **This is an important review on the challenges facing the pharmaceutical industry and how to address them.**
147. Kwan, P. *et al.* Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. *Epilepsia* **51**, 1069–1077 (2010).
148. Löscher, W. & Rundfeldt, C. Kindling as a model of drug-resistant partial epilepsy: selection of phenytoin-resistant and nonresistant rats. *J. Pharmacol. Exp. Ther.* **258**, 483–489 (1991). **This is the first paper to demonstrate that it is possible to select pharmacoresistant rats from epilepsy models and to use such animals for studying the mechanisms of resistance to epilepsy.**
149. Brandt, C., Volk, H. A. & Löscher, W. Striking differences in individual anticonvulsant response to phenobarbital in rats with spontaneous seizures after status epilepticus. *Epilepsia* **45**, 1488–1497 (2004).
150. Rogawski, M. A. The intrinsic severity hypothesis of pharmacoresistance to antiepileptic drugs. *Epilepsia* **54** (Suppl. 2), 32–39 (2013).
151. Leber, P. D. Hazards of inference: the active control investigation. *Epilepsia* **30** (Suppl. 1), S57–S63 (1989).
152. Herman, S. T. Clinical trials for prevention of epileptogenesis. *Epilepsy Res.* **68**, 35–38 (2006).
153. Sloviter, R. S. Progress on the issue of excitotoxic injury modification versus real neuroprotection; implications for post-traumatic epilepsy. *Neuropharmacology* **61**, 1048–1050 (2011).
154. Mani, R., Pollard, J. & Dichter, M. A. Human clinical trials in antiepileptogenesis. *Neurosci. Lett.* **497**, 251–256 (2011).
155. Goddard, G. V., McIntyre, D. C. & Leech, C. K. A permanent change in brain function resulting from daily electrical stimulation. *Exp. Neurol.* **25**, 295–330 (1969).
156. Ben Ari, Y., Tremblay, E., Ottersen, O. P. & Naquet, R. Evidence suggesting secondary epileptogenic lesion after kainic acid: pre treatment with diazepam reduces distant but not local brain damage. *Brain Res.* **165**, 362–365 (1979).
157. Vergnes, M. *et al.* Spontaneous paroxysmal electroclinical patterns in rat: a model of generalized non-convulsive epilepsy. *Neurosci. Lett.* **33**, 97–101 (1982).
158. Cavalheiro, E. A. *et al.* Long-term effects of pilocarpine in rats: structural damage of the brain triggers kindling and spontaneous recurrent seizures. *Epilepsia* **32**, 778–782 (1991).
159. Toman, J. E. P., Fine, E. A., Everett, G. M. & Henrie, L. M. Experimental psychomotor seizure in laboratory animals. *Electroencephalogr. Clin. Neurophysiol.* **3**, 102 (1951).
160. Löscher, W. in *Models of seizures & epilepsy* (eds Pitkänen, A., Schwartzkroin, P. A. & Moshé, S. L.) 551–566 (Elsevier, 2006).
161. Abou-Khalil, B. & Schmidt, D. in *Handbook of Clinical Neurology* Vol. 108 Part I. I. (eds Stefan, H. & Theodore, W. H.) 723–739 (Elsevier, 2012).

## Acknowledgements

The authors are very grateful to A. Vezzani, L. Kramer, E. Perucca and M. Rogawski for their comments and constructive criticisms on an earlier draft of the manuscript.

## Competing interests statement

The authors declare competing financial interests: see Web version for details.

## FURTHER INFORMATION

ClinicalTrials.gov website: <http://clinicaltrials.gov>  
NEMO Europe: <http://www.nemo-europe.com>  
Proximagen pipeline: <http://ljkonyx.co.uk/science/pipeline>  
US Food and Drug Administration 'Guidance for Industry' document (E 10 Choice of Control Group and Related Issues in Clinical Trials): <http://www.fda.gov/downloads/Guidances/UCM073139.pdf>

ALL LINKS ARE ACTIVE IN THE ONLINE PDF